Alpha Teknova Inc. (TKNO), a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, has reported strong financial results for 2024 compared to 2023.
For the fourth quarter ended Dec.31, 2024, the total revenue was $9.3 million, an 18 percent increase from $7.9 million in the same quarter of 2023.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com